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ABSTRACT The remarkable effectivity of current antiviral therapies has led to con-
sider the elimination of hepatitis C virus (HCV) infection. However, HCV infection is
highly underdiagnosed; therefore, a global strategy for eliminating it requires im-
proving the effectiveness of HCV diagnosis to identify hidden cases. In this study, we
assessed the effectiveness of a protocol for HCV diagnosis based on viral load reﬂex
testing of anti-HCV antibody-positive patients (known as one-step diagnosis) by ana-
lyzing all diagnostic tests performed by a central laboratory covering an area of 1.5
million inhabitants in Barcelona, Spain, before (83,786 cases) and after (45,935 cases)
the implementation of the reﬂex testing protocol. After its implementation, the per-
centage of anti-HCV-positive patients with omitted HCV RNA determination remark-
ably decreased in most settings, particularly in drug treatment centers and primary
care settings, where omitted HCV RNA analyses had absolute reductions of 76.4 and
20.2%, respectively. In these two settings, the percentage of HCV RNA-positive pa-
tients identiﬁed as a result of reﬂex testing accounted for 55 and 61% of all anti-
HCV-positive patients. HCV RNA results were provided in a mean of 2 days. The
presence of HCV RNA and age of 65 years were signiﬁcantly associated with ad-
vanced ﬁbrosis, assessed using the serological FIB-4 index (odds ratio [OR], 5.92; 95%
conﬁdence interval [CI], 3.4 to 10.4). The implementation of viral load reﬂex testing
in a central laboratory is feasible and signiﬁcantly increases the diagnostic effective-
ness of HCV infections, while allowing the identiﬁcation of underdiagnosed cases.
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Hepatitis C virus (HCV) infection is a major health problem worldwide. The overallprevalence of chronic HCV infection is estimated to amount to 71 million people
(1). Still, HCV infection continues to be considered an underdiagnosed disease, and it
is estimated that about half of the people infected might not be aware of it (2, 3). Based
on prevalence data from Spain, there might be over 200,000 cases of undiagnosed HCV
infections (4).
Last-generation direct-acting antivirals (DAAs) have reached cure rates of over 95%
Citation López-Martínez R, Arias-García A,
Rodríguez-Algarra F, Castellote-Bellés L, Rando-
Segura A, Tarraso G, Vargas-Accarino E,
Montserrat-Lloan I, Blanco-Grau A, Caballero-
Garralda A, Ferrer-Costa R, Pumarola-Sunye T,
Buti-Ferret M, Esteban-Mur R, Quer J, Casis-Saez
E, Rodríguez-Frías F. 2020. Signiﬁcant
improvement in diagnosis of hepatitis C virus
infection by a one-step strategy in a central
laboratory: an optimal tool for hepatitis C
elimination? J Clin Microbiol 58:e01815-19.
https://doi.org/10.1128/JCM.01815-19.
Editor Michael J. Loeffelholz, Cepheid
Copyright © 2019 López-Martínez et al. This is
an open-access article distributed under the
terms of the Creative Commons Attribution 4.0
International license.
Address correspondence to Francisco
Rodríguez-Frías, frarodri@vhebron.net.
Received 30 October 2019
Accepted 31 October 2019
Accepted manuscript posted online 6
November 2019
Published
VIROLOGY
crossm
January 2020 Volume 58 Issue 1 e01815-19 jcm.asm.org 1Journal of Clinical Microbiology
23 December 2019
 o
n
 January 27, 2020 at Queen M
ary, University of London
http://jcm.asm.org/
D
ow
nloaded from
 
and provide more beneﬁts when the disease is treated in its initial stages (5, 6). These
outstanding improvements in therapeutic tools have driven the proposal of strategies
to eradicate the HCV infection. Based on the initiative by the World Health Organiza-
tion, it is critical to identify infected individuals both to start therapy promptly and to
avoid spreading and the occurrence of new cases (7). However, in daily clinical practice,
the diagnostic process of HCV infections and patients’ hospital referrals usually require
multiple visits, which delays the diagnosis and increases the risk to lose the patient to
follow-up (8).
In our area (Catalonia, northeast Spain), in vitro diagnoses provided by the public
health care system, covering over 80% of a population of 7.5 million people, are
centralized in six laboratories (9). Ours, the largest in Spain, centralizes HCV-related
analytical tests from the entire primary care setting of a city with 1.5 million people
(Barcelona), plus several public health facilities, thus covering most entry points for new
HCV infections. This remarkable coverage offers an opportunity to increase the rate of
hepatitis C diagnosis by implementing new strategies driven by the laboratory.
Traditionally, HCV screening in outpatients starts with the request of antibodies
against HCV (anti-HCV) by physicians; in case of positive anti-HCV results, the physician
should request a new blood draw to test viral load (Fig. 1A). The medical visit and blood
extraction cannot be done on the same day because they are performed in different
centers: blood extractions are performed by specialized phlebotomists located at
speciﬁc sites, which centralize different medical consultations and require a prior
appointment. In addition to be very upsetting for the patient, this complex process is
highly prone to end up with a loss to follow-up of infected patients. In fact, a
remarkable proportion of anti-HCV-positive cases in our laboratory remain untested for
FIG 1 HCV infection diagnosis ﬂowchart in an ambulatory setting before (A) and after (B) the implementation of the reﬂex-testing-based
protocol or one-step protocol. aHCV, anti-hepatitis C virus antibody; VL, viral load.
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viral load. To reduce lost-to-follow-up rates, in 2015 our laboratory introduced a
strategy to promote viral load requests in new cases of patients who tested positive for
anti-HCV antibodies through comments in the analytical report. However, this action
did not meet our expectations. Therefore, following the recommendations of the
European Association for the Study of the Liver (EASL) (10), we implemented a one-step
diagnostic protocol, known as reﬂex testing, in which the sample collected for blood
count analysis is used to determine HCV RNA in anti-HCV-positive patients (Fig. 1B),
eliminating the need for the physician to request the test and notably reducing the
number of visits. In recent years, similar strategies aimed at reducing the number of
visits needed for diagnosis have been described (8, 11); however, there is very little
information on the impact of its implementation on the diagnosis of new cases.
Strategies aimed at optimizing screening programs seem to be essential to eradicate
HCV infections, as has been set as an objective by the World Health Organization (2).
This study presents the results of both screening protocols and a comparison of
their effectiveness at detecting new cases of HCV infection. Furthermore, considering
that the sequential use of a blood sample for blood count and HCV load analyses is a
key element of the one-step protocol, the integrity and suitability of viral RNA were also
assessed. Finally, and since the data obtained allowed determination of the degree of
ﬁbrosis using the FIB-4 score, its relationship with viral load was explored.
MATERIALS AND METHODS
Study design and diagnostic protocols. This study was an analysis of all HCV diagnostic tests
recorded in the laboratory information system (LIS) of Vall d’Hebron Barcelona Hospital (Spain)
between January 2015 and December 2018. The laboratory centralizes the analytical tests from a
1,200-bed hospital, as well as all samples coming from primary care centers and other public
facilities of Barcelona (1.5 million inhabitants). The study period encompasses two different diag-
nostic protocols: before March 2018, we actively recommended to perform HCV RNA determination
in anti-HCV-positive outpatients upon prior request by the health care provider (six-step protocol)
(Fig. 1A); whereas from March 2018, the laboratory used the whole-blood EDTA sample collected for
blood count analysis (hematimetry [hemocytometry]) to determine the HCV RNA in all anti-HCV-
positive patients (reﬂex testing or one-step protocol) (Fig. 1B). Results of the HCV RNA test were
provided within 24 h after anti-HCV testing, on Monday to Thursday, and within 3 days in case the
anti-HCV test was performed on a Friday. Serological testing (anti-HCV determination) was per-
formed on the Cobas 8000 platform (Roche Diagnostics, Germany) with single-use (i.e., disposable)
tips. In both protocols, the determination of HCV RNA was performed with a Cobas 6800 analyzer
(Roche Diagnostics, Germany); the blood count analysis prior to determination of HCV RNA was
performed by ﬂow cytometry with a Sysmex XN-20 analyzer (Sysmex Corporation, Japan). Therefore,
the sample used for HCV RNA had been previously used for hematimetry studies. However, the
Sysmex XN-20 analyzer can perform hematimetric measures without decapping blood tubes (the
rubber cap is punched by a needle). The potential use of serum samples previously collected for
serology was initially ruled out due to the higher risk of carryover. First, since the analyzer centralizes
serological determinations, the system tends to concentrate samples with suspected hepatitis C (i.e.,
is potentially anti-HCV positive). Second, although the Cobas 8000 analyzer uses disposable tips,
samples reach the analytical system uncapped and they are, therefore, exposed to environmental
aerosols and other occasional hand manipulations, which may increase the risk of contamination. In
contrast, all hematimetry determinations are randomly processed (more than 5,000 a day), meaning
that potential anti-HCV-positive cases (about 5 to 10 a day) would be randomly distributed among
these 5,000 samples, statistically reducing the probability of cross-contamination associated with
that of two anti-HCV-positive cases: one positive HCV RNA located near, and prior to, one negative
HCV RNA. In spite of this, a cross-contamination study was performed to ensure the quality and
adequacy of this type of sample. Said HCV RNA analysis is only carried out in those cases lacking any
data prior to the determination of the viral load (see the algorithm in Fig. 2).
Assessment of diagnostic protocols. The result of adding a recommendation to perform a HCV
RNA analysis in anti-HCV-positive outpatients was assessed using the data from the medical history
of non-hospital patients.
In order to assess and compare the effectiveness of both protocols, all cases from the following
periods were considered: January 2017 to February 2018 for the six-step protocol (82,786 cases), and
March 2018 to December 2018 after implementing the reﬂex-testing-based protocol for HCV RNA
(45,935 cases). The causes for omitting requests were assessed based on the information contained
in the patient’s medical history. Cases were classiﬁed based on the source of the request: primary
care (i.e., general population attended in community health centers), drug treatment centers (i.e.,
outpatient centers for drug dependence care and follow-up [“CAS” according to its initials in
Spanish]), hospital care (hospitalized patients, hospital consultations, and an external site special-
izing in imported and sexually transmitted diseases), itinerant blood samples (from patients who,
due to different reasons, are sequentially or even simultaneously treated by different units and thus
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FIG 2 Detailed ﬂowchart of the reﬂex-testing-based (one-step) protocol for HCV infection diagnosis.
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shared by the different groups mentioned above), and other sources (prisons and children’s care
homes).
Study of sample suitability and integrity. To assess the absence of sample contamination, a
carryover study of HCV RNA was conducted with samples already used for blood count performed by
ﬂow cytometry with Sysmex XN-20 (Sysmex Corporation, Japan). For this purpose, hematimetry samples
from 12 patients, the viral load of which had been previously analyzed using speciﬁc EDTA plasma
sample with the Cobas 6800 analyzer (Roche Diagnostics, Germany) were selected: three blood samples
(c1 to c3) had a viral load higher than 6 logs, and in nine blood samples (i1 to i9), the viral load was
undetectable. After selection of samples according to viral load, they were reprocessed in the Sysmex
XN-20 analyzer in the same analytical series, following this sequence: c1-c2-c3/i1-i2-i3/c1-c2-c3/i4-i5-i6/
c1-c2-c3/i7-i8-i9, which maximized the risk of carryover from cases with a high viral load to those with
an undetectable viral load: three samples with a high viral load followed by three samples with an
undetectable viral load. Afterwards samples were centrifuged, and HCV RNA was determined in those
samples containing a previously undetectable viral load.
To assess the stability of the HCV RNA viral load, 29 samples with a viral load higher than 4 logs were
selected. The viral load was determined the same day it was taken, at 24 and 72 h after being stored at
4 to 8°C. Results obtained were compared using the Wilcoxon test.
Liver ﬁbrosis assessment. The degree of liver ﬁbrosis was assessed using the FIB-4 index (12) in
serum samples of HCV RNA-positive patients during March to December 2018. The FIB-4 index is
currently considered a valid tool for assessing the degree of ﬁbrosis (10, 13), and allows identiﬁcation of
clinically signiﬁcant ﬁbrosis (F3) at the threshold of an FIB-4 score of 3.25 (4). The relationship
between patient’s age, degree of ﬁbrosis, and HCV RNA was also investigated. Means of the FIB-4 index
obtained for the different groups were compared using the Student’s t test. For the two factors being
investigated (age, detectable viral load, and both), the odds ratio (OR) for the presence of advanced
ﬁbrosis was estimated.
RESULTS
Sample suitability and integrity for reﬂex testing. Of the nine samples without
a tested detectable viral load, seven remained free of HCV RNA, while amounts lower
than the quantiﬁcation limit of the analytical process were detected in two samples
(15 IU/ml). Regarding the integrity of HCV RNA over time, the Wilcoxon test did not
reveal any signiﬁcant differences in its levels throughout the period of conservation of
the samples.
Result of the six-step protocol with active recommendation. Between January
2015 and March 2018, anti-HCV antibody determination was performed in 140,329 patients
from primary care centers, of which 5,436 (3.9%) tested positive for anti-HCV. In 2,716 (50%)
anti-HCV-positive patients, the laboratory included a recommendation to perform an HCV
RNA analysis in the printed and online result reports, which was followed in 1,412 cases
(52% of all recommendations), and the determination of HCV RNA was therefore requested
TABLE 1 Total cases analyzed under the traditional protocol (from January 2017 to February 2018) and the reﬂex testing (one-step)
protocol (from March 2018 to December 2018)
Settinga
No. (%) with result by:
6-step protocol Reﬂex testing protocol
n aHCV positive
HCV RNA
analysisb
HCV RNA
analysis
omittedc
Detectable
HCV RNA n aHCV positive
HCV RNA
analysisb
HCV RNA
omittedc
Detectable
HCV RNA
Hospital care 20,446 2,583 (12.6) 2,998 1,697 (8.3) 979 (32.7) 10,740 616 (5.7) 831 70 (11.4) 191 (23.0)
Non-hospital care 62,340 2,612 (4.2) 1,885 776 (29.7) 752 (39.9) 35,195 1,126 (3.2) 1,093 82 (7.3) 458 (41.9)
CAS 1,335 211 (15.8) 39 172 (81.5) 21 (53.8) 1,052 235 (22.3) 245 12 (5.1) 132 (53.9)
Itinerant 2,644 383 (14.5) 360 35 (9.1) 199 (55.3) 401 53 (13.2) 57 2 (3.8) 30 (52.6)
Primary care 57,830 2,010 (3.5) 1,480 570 (28.4) 530 (35.8) 33,399 831 (2.5) 784 68 (8.2) 295 (37.6)
Other 531 8 (1.5) 6 2 (25.0) 2 (33.3) 343 7 (2.0) 7 0 1 (14.3)
Total 82,786 5,195 (6.3) 4,883 2,476 (47.7) 1,731 (35.4) 45,935 1,742 (3.8) 1,924 152 (8.7) 649 (33.7)
a“Primary care” represents the general population seeking treatment in a community health center, “CAS” represents drug treatment centers, “Hospital care” represents
hospitalized patients, hospital consultations, and an external site specialized in imported and sexually transmitted diseases, “Itinerant” represents patients who for different
reasons are sequentially or even simultaneously treated by different units and thus are shared by the different groups mentioned above, and “Other” represents prisons and
children’s care homes.
bThe number of HCV RNA analyses may be greater than the number of aHCV (anti-hepatitis C virus antibody)-positive analyses because some patients were previously
known to be aHCV positive and serology was not repeated.
cThe percentage of omitted HCV RNA analyses was based on the number of patients with aHCV without HCV RNA determination (either before or after) at the time of
data collection. In the case of the reﬂex testing protocol, all omitted analyses were due to technical issues.
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and performed. Of all cases in which the recommendation was omitted, 986 (36%)
corresponded to HCV patients with known infection, whereas in 327 (12%) cases, the
reason for omitting HCV RNA determination was unknown.
Result of implementing the one-step protocol. During the entire period analyzed
(2017 to 2018), a total of 128,721 cases were collected (Table 1). During the six-step protocol
period, omitted HCV RNA analyses ranged from 8% to 82% of all anti-HCV-positive patients.
The setting in which less HCV RNA tests were requested for anti-HCV-positive patients in
this period was drug treatment centers (CAS) (82%), followed by primary care settings(28%).
After implementation of the one-step protocol (based on reﬂex testing), the percentage of
HCV RNA tests that were omitted in anti-HCV-positive patients was11% in all settings. In
the case of drug treatment centers and primary care settings, the absolute percentages of
omitted HCV RNA analyses decreased 76.4% (from 81.5% to 5.1%) and 20.2% (from 28.4%
to 8.2%), respectively. Table 1 shows the number of cases with detectable HCV RNA, and
Table 2 shows the range and median of HCV RNA levels for each group.
Of the 1,924 anti-HCV-positive patients with HCV RNA determination in the second
analysis period (i.e., after implementing the reﬂex testing protocol), 1,034 (53.7%) had been
requested by the physician, whereas 890 (46.3%) were performed as reﬂex testing despite
not having been requested (Table 3). The result of the HCV RNA analysis was provided in
a mean of 2 days after anti-HCV determination. In the primary care setting, of the 295
patients with detectable HCV RNA during this period, the reﬂex testing had been per-
formed on 163 (55.3%), despite the fact that the doctor had not requested it. In the case of
drug treatment centers, positive HCV RNA identiﬁed thanks to reﬂex testing amounted to
60.6% of the total.
Liver ﬁbrosis evaluation. All data necessary to establish the FIB-4 index were available
in our LIS in 869 (77%) of 1,126 anti-HCV-positive outpatients analyzed between March and
December 2018. Both age and the presence of HCV RNA were signiﬁcantly associated with
the FIB-4 score and the three degrees of ﬁbrosis: advanced, absence, and undetermined
(Table 4). The ORs of advanced ﬁbrosis associated with age of 65 years and detectable
levels of HCV RNA were 5.2 (95% conﬁdence interval [CI], 3.3 to 7.9) and 3.6 (95% CI, 2.2 to
5.8), respectively. Taken together, patients aged 65 years or older with detectable levels of
HCV RNA had an OR of 5.92 (95% CI, 3.4 to 10.4) of having advanced ﬁbrosis.
DISCUSSION
The results from this study show how the application of a viral load reﬂex testing (or
one-step) protocol for the diagnosis of HCV infections in a central laboratory allows an
outstanding increase in diagnostic rates, particularly in the primary care setting, which in
our discipline entails the main entry point for new cases of HCV infection, and drug
treatment centers, where hepatitis C has the highest prevalence in our area (21%).
To implement this screening protocol, it was essential to ﬁrst ensure the suitability of the
sample in which the viral load was to be determined. The fact that the ﬂow cytometry
analyzer keeps samples capped while processing them—thus preventing contact with
TABLE 2 HCV RNA levels in cases detected by the reﬂex testing (one-step) protocol (from March 2018 to December 2018)
Setting
No. of patients with detectable
HCV RNA
HCV RNA level (IU/ml) in group
Minimum Maximum Median
Hospital care 191 15 7.4  107 2.2  106
Non-hospital care 458
CASa 132 16 2.1  107 1.2  106
Itinerant 30 47 1.2  107 1.5  106
Primary careb 295 114 4.6  107 1.7  106
Other 1 NAc NA NA
Total 649
aFour cases with an HCV RNA level of 15 IU/ml were observed.
bOne case with an HCV RNA level of 15 IU/ml was observed.
cNA, not applicable.
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aerosols and environmental RNAses—strongly reduced the likelihood of contamination
and deterioration of viral RNA. Furthermore, the probability of a sample free of HCV RNA
matching a sample with a detectable viral load in the same analytical sequence was in fact
much lower than the probability of both samples coexisting in the same anti-HCV antibody
determination sequence in the serology analyzer (even taking into account the low
probability in the Cobas 8000 analyzer due to the use of disposable tips). Despite the a priori
favorable conditions to implement the reﬂex testing protocol, an occasional error in the
washing system of the blood count analyzer could cause minimal contamination, like that
observed in two of the nine analyzed samples in which HCV RNA was detected, although
in amounts below the quantiﬁcation limit of 15 IU/ml. In this regard, it is important to
mention that, in naive patients, viral loads have been previously reported to be3 logs in
a very high proportion (EASL guidelines) or even 2 logs based on our own experience
(14). In fact, in the cases analyzed in this study, after application of the HCV RNA reﬂex
testing, only nine cases (one in the primary care setting and eight in the CAS setting)
showed HCV RNA levels of2 logs. Among them, only ﬁve cases with levels of 15 IU/ml
(four in CAS and one in primary care) were observed, which, after further investigation, were
all related to antiviral treatment. Hence, a value of 15 IU/ml should be considered
irrelevant in the context of a new diagnosis (10). Still, faced with this potential risk, the need
to evaluate the viral load in a new sample in cases with an HCV RNA level of 2 logs was
included in the protocol (Fig. 2). Given the sampling path in our area, the sample collected
for blood count analysis seems to be optimal for viral load reﬂex testing; however, other
type of samples processed before could be used, provided that their adequacy (i.e., stability
and lack of contamination) has been assessed. This possibility is also indicated in our
recommended algorithm, which in fact is currently being implemented in all Catalonia.
In our experience, the traditional protocol, in which patients needed six visits for a full
diagnosis (Fig. 1A), had a low ratio of HCV RNA conﬁrmatory tests, especially in the
ambulatory setting (non-hospital care), where the HCV RNA analysis was omitted in 9 to
82% of cases, depending on the source of the sample. This omission was particularly
worrisome in the primary care setting, where HCV RNA analysis was omitted in the 28% of
the around 2,000 anti-HCV-positive subjects from a total population of 58,000 individuals.
These data conﬁrm the low percentage of HCV RNA conﬁrmatory test performance (46% to
73%) observed in protocols with multiple visits (8). Improvements observed after imple-
menting the new one-step protocol were particularly notorious in the ambulatory setting
(outpatients), with increases from 18% to 95% of HCV infection cases in CAS and from 72%
to 92% in primary care centers: the contributions of reﬂex testing to the identiﬁcation of
new cases in these care settings were 54% and 28%, respectively. The spectacular increase
in diagnostic rates in drug treatment centers is particularly relevant in terms of public
health, due to the high prevalence of HCV infection among drug users. An effective
diagnosis in this setting enables starting antiviral treatment, likely to result in HCV curation
(15), a key cornerstone for HCV infection elimination (2, 7). However, a low rate of
anti-HCV-positive cases remain undiagnosed due to lack of viral load testing; in our case,
most are due to lack of hematimetry requests, meaning no samples for HCV RNA testing.
In these cases, the validation of other types of samples, such as one’s own sample
TABLE 3 HCV RNA detected during the period from March to December 2018 based on the source of the analysis request
Setting
No. (%) of results with:
HCV RNA analysis requested HCV RNA analysis not requested (reﬂex testing only)
Determination of HCV RNA (n 1,034)a HCV RNA detected Determination of HCV RNA (n 890)a HCV RNA detected
Hospital care 704 (84.7) 161 (22.9) 127 (15.3) 30 (23.6)
Non-hospital care 330 (30.2) 763
CAS 97 (39.6) 52 (53.6) 148 (60.4) 80 (54.1)
Itinerant 23 (40.4) 16 (69.6) 34 (59.6) 14 (41.2)
Primary Care 206 (26.3) 132 (64.1) 578 (73.7) 163 (28.2)
Other 4 (57.1) 1 (25.0) 3 (42.9) 0
aPercentages are over the total number of assessments in a given setting.
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previously processed for serology, could be used for viral load reﬂex testing. However, this
would require conducting a prior study ensuring its use, such as that performed here
regarding hematimetry tubes.
Aside from the beneﬁts of this technique at the level of public health, reﬂex-testing-
based diagnosis means fewer visits to the doctor and unnecessary blood draws. This, in
turn, translates into not only more comfortable patients, but also fewer subjects lost to
follow-up and a shorter delay time for diagnosis and referral to a specialized center to
receive treatment. It is noteworthy that the reﬂex testing protocol provided a diagnosis
within a mean of 2 days, in contrast with the six-step protocol, which lasted weeks—or
even months—due to administrative barriers to scheduling extra appointments. In addi-
tion to a shorter time for diagnosis, previous studies have found that the application of
similar protocols are cost-effective (16). In this regard, it is important to highlight that the
cost of a viral RNA determination (less than 30 euros in our laboratory) is much lower than
the cost of a physician appointment and a blood extraction, so overall cost reduction may
be of note. Furthermore, our algorithm includes request containment tools, such as
avoiding duplicated determinations for patients with previous positive anti-HCV test results.
Alternative methods for testing for HCV infection outside of a central laboratory, such as
the rapid diagnostic test (RDT) with capillary ﬁnger blood (e.g., OraQuick HCV) (17), have
higher costs (i.e., 15 euros per test or higher) and poorer outcomes (98% of correspon-
dence). However, these methods can be beneﬁcial in areas or population groups where the
implementation of central laboratory strategies is unreliable (e.g., active drug users).
Notwithstanding the beneﬁts of other methods, central laboratory methodologies are
strongly recommended by international guidelines for populations outside of the normal
health system as well, thus allowing the implementation of one-step strategies, irrespective
of the type of sample used. An example of an alternative sampling has been described by
Lazarus et al., who implemented a one-step diagnosis strategy using whole blood sampled
on dried blood spots (18). In this regard, the use of the GenXpert platform (Cepheid,
Sunnyvale, CA, USA), which has shown an extremely optimal correlation with high-
throughput systems (19, 20), represents an adequate alternative for HCV viral load deter-
mination when it is not possible to perform it in a central laboratory. This is the case of
special populations like, for instance, active intravenous drug users, in which it seems
advisable to conduct any viral load testing at the same center and start antiviral treatment
as soon as possible. In these cases, the extreme high prevalence of HCV infections (70%
seroprevalence according to a recent meta-analysis) (21) would even make direct screening
of viral loads cost-effective by means of GenXpert technology (Cepheid) in the same drug
treatment center. However, in addition to the possibility of a concomitant determination of
blood count and HCV RNA, HCV diagnosis with venipuncture for standard blood sampling
in central laboratories had the advantage of the possibility of assessing patients’ liver
ﬁbrosis, which is necessary for their management in case of liver cirrhosis or advanced
ﬁbrosis (10, 22). In this regard, an HCV diagnosis strategy encompassing the FIB-4 index
assessment promotes the patient’s start of treatment, while raising awareness on patients
TABLE 4 Degree of ﬁbrosis of anti-HCV-positive patients analyzed during the period from March to December 2018 according to age
and positive/negative HCV RNA
Parametera
Result for parameter by:
Age
P
HCV RNA
P>65 yr (n 183) <65 yr (n 686) Negative (n 399) Positive (n 402)
FIB-4 score, mean (95% CI) 3.09 (2.73–3.44) 1.57 (1.45–1.69) 0.001 1.52 (1.39–1.66) 2.27 (2.05–2.49) 0.001
Fibrosis grade, n (%)
Advanced ﬁbrosis 52 (28.4) 49 (7.1) 23 (5.8) 71 (17.7)
Absence of ﬁbrosis 24 (13.1) 447 (65.2) 0.0001 259 (64.9) 176 (43.7)
Undetermined 108 (58.8) 190 (27.7) 117 (29.3) 155 (38.6)
aCI, conﬁdence interval. The degree of ﬁbrosis was deﬁned based on the FIB-4 score according to the following cutoffs: 3.25 for advanced ﬁbrosis (65% positive
predictive value and 97% speciﬁcity) and 1.45 for absence of ﬁbrosis (90% negative predictive value and 70% sensitivity). Scores between 1.45 and 3.25 were
considered undetermined.
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with advanced ﬁbrosis. Clinical Practice Guidelines recommend combining noninvasive
biomarker-based measurements, such as the FIB-4 index, with physical examinations, such
as transient elastography (TE); however, not all sites have this technology (23). Aside from
the high positive and negative predictive values of FIB-4 for the diagnosis of advanced
ﬁbrosis and cirrhosis (24, 25), combining the FIB-4 index and the TE examination in
sequence increases the accuracy of the diagnosis of the ﬁbrosis stage (26). The results found
in this study show the high probability of advanced ﬁbrosis in patients with a detectable
viral load (17%) and those over 65 years of age (28%). These data provide a global vision of
the signiﬁcance of the degree of liver ﬁbrosis in these patients and the importance of
diagnosing the state of the infection early.
The extremely positive development of hepatitis C therapies is being darkened by the
sad reality that the majority (80%) of people with chronic HCV infections remain undiag-
nosed (2). Achieving the WHO objective of eliminating viral hepatitis as a major public
health threat by 2030 will require urgent strategies facilitating a massive scale-up of timely
diagnoses as an essential step to drive infected individuals to treatment. It must be kept in
mind that late diagnosis and treatment of chronic HCV infections may result in severe
consequences for the health of both the individual and the population. In this regard, 30%
of HCV-infected patients with late diagnosis will beneﬁt less from achieving viral elimina-
tion, as well as those with advanced liver disease who are at high risk of developing
decompensated cirrhosis, portal hypertension, and hepatocellular carcinoma (2, 27, 28). The
occurrence of late chronic hepatitis C should be assumed as a failure of the health system
to timely diagnose infected individuals. Overcoming this issue will require to promote early
screening using a strategy as effective and simple as possible. Since the reﬂex testing
strategy is driven by—and depends on—a central laboratory, patient treatment start
(including the assessment of liver ﬁbrosis) can be achieved without implementing sophis-
ticated and expensive screening programs.
Our analysis has the typical limitations of an observational study in which all data have
been obtained from a record designed with purposes of care and laboratory operations
management. This design has allowed us to bring together data from 128,721 patients,
providing an accurate perspective of the population reality; however, no patient social-
demographic and clinical information could be collected, which could have improved the
study. Furthermore, wemust bear in mind that the scope of the results may be conditioned
by the organization of the health care system and the laboratory itself, so, depending on
the context, the contribution of the one-step protocol to the diagnosis of new cases of HCV
could be lower or even higher.
In summary, our study shows the potential that implementing a diagnostic protocol
based on reﬂex testing in a central laboratory may have to identify new cases of HCV
infection signiﬁcantly faster (2 days instead of weeks or months) and with much higher
effectiveness than the traditional six-step process. Although results must be interpreted
within the context of laboratory practice and the health care system of each area, our
experience encourages the implementation of this type of analyses, which may notably
contribute to the elimination of HCV infections. In this regard, it seems evident that
universal screening programs for HCV infection represent the optimal solution to detect
hidden HCV cases and start treatment, thus meeting the WHO aims. Given that the general
population is mostly managed in the primary care setting, one-step diagnosis programs can
effectively cover a high proportion of the general population at a low cost. Overall, the
cost-effectiveness of implementing hepatitis C screening programs in the general adult
population has been demonstrated (29). The availability of high-performance analytical
platforms like Cobas 8000 and Cobas 6800, used in our laboratory and able to process
thousands of samples in a normal working day, strongly facilitates the implementation of
such screening programs. However, additional strategies for groups at high risk, very
frequently not linked to the health system, might be necessary to reach the entire
population of HCV-infected individuals. In this regard, the accurate and simple point-of-care
testing platforms, specially the HCV ﬁnger-stick assay in the GenXpert analyzer (Cepheid),
represent a very interesting alternative for these special populations.
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